Please login to the form below
Hodgkin lymphoma
This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
ASCO: Momentum gathers behind next wave of CAR-T therapies
Yescarta (axicabtagene ciloleucel) achieved a 93% overall response rate (ORR) in patients with relapsed or refractory indolent (slow growing) non-Hodgkin’s lymphoma (NHL), with 80% of them classed as having ... Among these, Allogene and Servier’s CD19
Latest news
-
EMA starts review of MorphoSys’ tafasitamab for lymphoma
grade lymphoma – in adults who are not candidates for a stem cell transplant. ... DLBCL is the most common type of non-Hodgkin’s lymphoma (NHL) in adults worldwide accounting for 40% of all cases, and is a very aggressive disease – around 30-40% of
-
Keytruda hits primary endpoint in confirmatory lymphoma trial
Interim analysis demonstrates improvement in progression-free survival. Merck &Co/MSD’s Keytruda has hit the primary endpoint in a confirmatory phase 3 trial in classical Hodgkin lymphoma (cHL), three years ... Patients with classical Hodgkin lymphoma
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours – colorectal, ovarian and bladder cancer.
-
Celgene’s Revlimid scores NICE approval in follicular lymphoma
lymphoma. Follicular lymphoma is the most common type of low-grade non-Hodgkin’s lymphoma, and despite having a median overall survival rate of over 15 years, patients are prone to ... Lenalidomide is a new type of targeted cancer therapy for people
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
MCL is an aggressive type of non-Hodgkin’s lymphoma, and although it responds well to initial treatment, it eventually stops responding and the cancer cells continue to multiply. ... Gilead/Kite’s approved CAR-T therapy Yescarta (axicabtagene
More from news
Approximately 6 fully matching, plus 204 partially matching documents found.
Latest Intelligence
-
Chinese biotech’s global ambitions
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
-
Deal Watch November 2016
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
-
Deal Watch June 2016
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Pharma deals in April 2015
Under the terms of the deal, Celgene has the rights to develop the product for non-Hodgkin lymphoma (NHL), myelodysplastic syndromes and multiple myeloma. ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL)
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Charles Morris appointed chief development officer at ImmunoGen
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Australian Flu and the dilemma of naming diseases
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Therapy Watch expands its oncology portfolio
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
-
Oncology drugs under AMNOG
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
